Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

Eric R. Lutz; Heather Kinkead; Elizabeth M. Jaffee; Lei Zheng

doi:10.4161/21624011.2014.962401

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

Eric R. Lutz, Heather Kinkead, Elizabeth M. Jaffee, Lei Zheng

School of Medicine

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

Original language	English (US)
Pages (from-to)	e962401-1-e962401-3
Journal	OncoImmunology
Volume	3
Issue number	11
DOIs	https://doi.org/10.4161/21624011.2014.962401
State	Published - Nov 2 2014

Keywords

pancreatic cancer
tumor immunotherapy
tumor vaccines

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/21624011.2014.962401

Cite this

@article{c7eae6db9e21452a937d61f8386f2785,

title = "Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy",

abstract = "Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.",

keywords = "pancreatic cancer, tumor immunotherapy, tumor vaccines",

author = "Lutz, {Eric R.} and Heather Kinkead and Jaffee, {Elizabeth M.} and Lei Zheng",

note = "Publisher Copyright: {\textcopyright} 2014 Taylor & Francis Group, LLC.",

year = "2014",

month = nov,

day = "2",

doi = "10.4161/21624011.2014.962401",

language = "English (US)",

volume = "3",

pages = "e962401--1--e962401--3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "11",

}

TY - JOUR

T1 - Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

AU - Lutz, Eric R.

AU - Kinkead, Heather

AU - Jaffee, Elizabeth M.

AU - Zheng, Lei

PY - 2014/11/2

Y1 - 2014/11/2

N2 - Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

AB - Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

KW - pancreatic cancer

KW - tumor immunotherapy

KW - tumor vaccines

UR - http://www.scopus.com/inward/record.url?scp=84938635509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938635509&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.962401

DO - 10.4161/21624011.2014.962401

M3 - Article

C2 - 25941589

AN - SCOPUS:84938635509

SN - 2162-4011

VL - 3

SP - e962401-1-e962401-3

JO - OncoImmunology

JF - OncoImmunology

IS - 11

ER -

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this